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Abstract
Background: Despite the accumulation of research papers on aspirin and cancer, there 
is doubt as to whether or not aspirin is an acceptable and effective adjunct treatment of 
cancer. The results of several randomised trials are awaited, and these should give clear 
evidence on three common cancers: colon, breast and prostate. The biological effects of 
aspirin appear likely however to be of relevance to cancer generally, and to metastatic 
spread, rather than just to one or a few cancers, and there is already a lot of evidence, 
mainly from observational studies, on the association between aspirin and survival in a 
wide range of cancers.
Aims: In order to test the hypothesis that aspirin taking is associated with an increase 
in the survival of patients with cancer, we conducted a series of systematic literature 
searches to identify clinical studies of patients with cancer, some of whom took aspirin 
after having received a diagnosis of cancer.
Results: Three literature searches identified 118 published observational studies in 
patients with 18 different cancers. Eighty-one studies report on aspirin and cancer mor-
tality and 63 studies report on all-cause mortality. Within a total of about a quarter of a 
million patients with cancer who reported taking aspirin, representing 20%–25% of the 
total cohort, we found aspirin to be associated with a reduction of about 20% in cancer 
deaths (pooled hazard ratio (HR): 0.79; 95% confidence intervals: 0.73, 0.84 in 70 reports 
and a pooled odds ratio (OR): 0.67; 0.45, 1.00 in 11 reports) with similar reductions in 
all-cause mortality (HR: 0.80; 0.74, 0.86 in 56 studies and OR: 0.57; 0.36, 0.89 in seven 
studies). The relative safety of aspirin taking was examined in the studies and the cor-
responding author of every paper was written to asking for additional information on 
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but fatal bleeding was rare and no author reported a significant excess in fatal bleeds associated with aspirin. No author mentioned cerebral 
bleeding in the patients they had followed.
Conclusions: There is a considerable body of evidence suggestive of about a 20% reduction in mortality in patients with cancer who take 
aspirin, and the benefit appears not to be restricted to one or a few cancers. Aspirin, therefore, appears to deserve serious consideration as 
an adjuvant treatment of cancer, and patients with cancer, and their carers, have a right to be informed of the available evidence.
Keywords: aspirin, cancer, survival, mortality, bleeding, thromboembolism
Introduction
The first suggestive evidence of benefit to patients with cancer from aspirin was reported over 50 years ago. Studies of animals with cancer 
showed that aspirin is associated with a reduction in the development of metastases [1, 2]. Since then, despite the reporting of much further 
evidence on biological effects of aspirin, and the reporting of many studies on aspirin and survival, there is still uncertainty about the role of 
aspirin as a possible adjuvant treatment of patients with cancer.
A number of small and inadequate randomised trials have been reported [3–6] and the pooling of results from these gives a suggestive reduc-
tion of 9% in cancer deaths in the 722 patients with cancer who had been randomised to aspirin (hazard ratio (HR): 0.91; 95% confidence 
interval (CI): 0.79, 1.04) [7]. While this result is only suggestive, a trial which developed within the cohort of the US Physicians Health Study 
of cancer prevention by aspirin is more strongly supportive. Just over 500 subjects in the cohort developed cancer, and those who had been 
randomised to aspirin showed a reduction in cancer deaths (HR: 0.68, 95% CI: 0.52, 0.90) [8].
Another source of evidence on the range of cancers to which aspirin may be relevant comes from opportunistic long-term follow-up studies 
of patients who had been involved in early randomised trials of aspirin and vascular disease. In addition to reporting a subsequent reduction 
in cancer incidence, Rothwell et al [9] and Mills and Wu [10] showed that deaths from a wide range of cancers were reduced in subjects who 
had been randomised to aspirin, and furthermore, the occurrence of metastatic spread was reduced in a range of cancers, including colon, 
brain, liver, lung and ‘other or multiple sites’ [11].
A number of new ad hoc randomised trial have been set up to test aspirin treatment in a few cancers and results from these are awaited 
[12–15]. These, however, are testing aspirin in only a very few cancers – principally colon, but also breast and prostate – while the effects of 
aspirin on biological mechanisms relevant to cancer lead to the possibility of benefit in most, if not all cancers [16–18]. Indeed, because of its 
manifold effects on biological processes, Zhang et al [19] suggest that aspirin is ‘a master regulator of the hallmarks of cancer’.
The bulk of published evidence on aspirin and the treatment of cancer comes, however, from observational studies and in this report, we 
present the results of 118 published observational studies to test the hypothesis that aspirin is of benefit to a wide range of cancers and not 
just one or a few common cancers. We also present evidence that aspirin, relative to cancer and in comparisons with other cancer treatments, 
is a very safe drug.
Methods
We conducted three consecutive systematic literature searches and meta-analyses of published observational studies of aspirin taken by 
patients with cancer. Detailed reports on the first two searches have been published [7, 20]. A description of the most recent search proce-
dure is given in Supplementary File 1, and in Supplementary File 2 a brief description of each of the studies judged to be relevant in the most 
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Given that most of the available studies have been on the three common cancers: colon, breast and prostate, and in view of the fact that 
aspirin is being tested in randomised trials, we first present pooled evidence on aspirin and these three cancers. We then present evidence 
from 36 published reports of 15 other cancers, each of which has been examined in only one or a very few studies.
The procedures adopted followed the PRISMA guidelines throughout [21] and a full description of the search strategy is given in Supple-
mentary File 1. In brief: each of the three systematic searches using keywords was conducted by AW and DM in MEDLINE and EMBASE. 
The searches were limited to human studies in peer-reviewed journals. Relevant studies were selected by two authors (PE and GM) if (a) the 
studied population comprised patients diagnosed with cancer; (b) aspirin appears to have been taken regularly after cancer diagnosis; (c) the 
studies were randomised trials, case–control studies or cohort studies. Reference lists of the relevant studies identified were searched for 
other relevant reports. At least one author on each selected paper in all three searches was written to and asked specifically about gastroin-
testinal (GI) bleeding in the patients included in their study, together with appropriate further questions.
Data on cancer deaths and deaths from all-causes in the most recent search to March 2020 are listed in Supplementary File 3, first for studies 
that had expressed association as HRs, followed by studies which had used odds ratios (ORs), risk ratios (RRs) or percent survival. The meth-
odological quality of the studies was assessed and graded independently by two authors (AW and PE) using the Newcastle–Ottawa Scale 
[22]. We have also added to each paper listed in Supplementary File 3 a comment as to the level of certainty that aspirin had been taken – or 
had not been taken – throughout follow-up.
Most of the risk estimates reported by the authors were expressed as HRs, and these and their 95% CI were taken from the original articles 
and log-transformed to obtain the estimate of the treatment effect (TE). The standard errors (seTE) were determined by subtracting the lower 
log-transformed CI boundary from the upper log-transformed CI boundary and dividing this by 3.92 (2*1.96). Where HRs were not reported, 
ORs, RRs and their 95% CI, or number of events among patients taking aspirin and those not on aspirin, were taken from the original articles. 
ORs and exact 95% CIs were calculated where needed, and all were then log-transformed for meta-analysis.
Summary risk estimates of random effects models are shown as forest plots in Supplementary File 4. HR meta-analyses were conducted 
using the meta package, version 4.13.0 in R 4.0.2, open source. Analysis with the metagen function used sm = HR for the underlying summary 
method and the DerSimonian–Laird method [23] was used to estimate the between-study variance (τ and τ2). Meta-analyses of the reports 
as ORs were conducted using Stata/SE 16.1, and used the restricted maximum likelihood method to estimate the between-study variance 
and these are shown as forest plots in Supplementary File 5.
Finally, funnel plots were constructed and estimates of the probability of publication bias were derived. The forest plot added trim and fill 
which mirrored the studies followed by a cumulative forest plot based on decreasing standard error. This was only undertaken on a minimum 
of 10 papers hence there is only one examination for OR. These are all shown in Supplementary File 6.
Results
Three systematic literature searches on the topic of this report were conducted by the authors: in 2016 [7], in 2018 [20] and in 2020 up to 
March 2020 (Supplementary File 1). In each report, there are two outcomes, death from cancer and death from any cause, almost all of which 
have been presented as HRs. The new studies are described in Supplementary File 3 and their results are listed and pooled in Supplementary 
File 4. Some of the deaths have however been reported as OR, relative risk, etc., and all these have been converted to ORs. These ORs are 
presented separately from the HRs in Supplementary File 3 and are listed and pooled in Supplementary File 5. Some results however have 
been presented as additional survival in months or years, or during defined periods of time, such as 5 years. These are mentioned in the text, 
but do not appear in any table or Supplementary file.
In addition, we were concerned about undesirable side effects of the aspirin and in addition to abstracting relevant data from the published 
reports, following each of the three searches we wrote to an author of every report, asking for details of any unwanted side effect and in 
particular bleeding attributable to aspirin. A few authors supplied evidence on bleeding further to that in their published report, and these 
details are quoted in the text.
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Figure 1. Flow diagram describing the findings of the three systematic literature searches.
Mortality
For colon cancer mortality, our three literature searches identified a total of 24 studies in which the association with aspirin was reported as 
HRs. Together, these give a pooled HR of 0.72 (95% CI: 0.63, 0.82), and a single report showed an OR (OR of 0.78 (0.66, 0.93) (Table 1 and 
Supplementary File 4). For all-cause mortality, 20 studies of colon cancer reported HRs, giving a pooled association with aspirin of 0.83 (95% 
CI: 0.75, 0.92) and a single HR reported an OR of 0.78 (0.65, 0.92) (Table 1 and Supplementary File 4)
For breast cancer mortality, 13 studies reported as HRs and these give a pooled HR: 0.84 (0.72, 0.98). Four further studies give pooled OR: 
0.75 (0.36, 1.57). For all-cause mortality in the breast cancer studies, nine reports give a pooled HR of 0.94 (0.70, 1.25).
For prostate cancer mortality, the pooling of 15 studies gives an HR of 0.89 (0.78, 1.02) and there was one study with an OR of 1.02 (0.78, 
1.34). For all-cause mortality in prostate cancer reports, seven studies give an HR of 1.00 (0.78, 1.27) and in one the OR is 1.06 (0.94, 1.19).
For cancers other than colon, breast and prostate, the supplementary files list ‘other’ cancers: nasopharynx [96, 102], GI cancers, including 
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bladder [98, 112, 114], ovary [81, 83–86, 113], endometrium [87, 89], head & neck [88, 90–92, 104, 123], lung [82, 94, 108, 122], leukaemia 
[79], glioma [100], melanoma [99] and two [39, 80] present a mixture of cancers.
Not all the estimates of association in these reports of ‘other’ cancers are significant at p < 0.05. However, only three are consistent with an 
oropharynx possible harmful effect of aspirin, having a confidence limit which includes 1, but none of the three is significant at p < 0.05 with 
both confidence limits above 1.
Together, these reports of ‘other’ cancers give a pooled HR for cancer mortality of 0.79 (0.70, 0.88) in 18 studies and a pooled OR of 0.49 
(0.26, 0.95) in five studies. All-cause mortality in 21 of these other cancers gives a pooled HR of 0.67 (0.60, 0.75) in 21 studies and the five 
studies that did not report HRs give a pooled OR of 0.47 (0.26, 0.83).
The forest plots of all these data are shown in Supplementary Files 4 and 5, and Table 2 brings together all the available data on cancer deaths 
and on all-cause mortality.
Table 1. Summary of Eggers test for bias and of trim and fill analysis.
Egger’s test Effect before trim and fill Results robust after trim and fill? Confidence interval after trim and fill
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There was no effect
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n=6
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Table 2. A summary of the overall findings of the association between aspirin taking and mortality in 106 reports.
Group Pooled estimates (Random effects model)
Cancer mortality All-cause mortality


















































aOther cancers: Nasopharyngeal, Oropharyngeal, Oesophagus, Gastric, Rectal, Liver, Gallbladder, Pancreas, Bladder, 
Endometrium, Ovary, Glioma, Head & Neck, Lung, Melanoma
A number of authors give estimates of the association with aspirin in terms of the duration of the additional survival in patients taking the 
drug. Thus, Albandar [117] who followed 174 US veterans with colorectal cancer to death reported that the median survival of patients tak-
ing aspirin was 941 versus 384 days in those not taking aspirin. Several papers record an increased survival associated with aspirin taken 
by patients with liver cancer: in one 18 months additional survival [93]; in another 6% more patients survived 10 years with aspirin after 
diagnosis [103], and the median overall survival period after embolisation was longer for patients taking aspirin (57 versus 23 months) [119]. 
In a study of endometrial cancer, 91% of patients taking aspirin survived 10 years compared with 81% of patients not on aspirin [87]. In a 
study of patients with lung cancer, patients on aspirin survived 1.69 and only 1.02 years if not on aspirin [96]. In a study of pancreatic cancer, 
the 3-year survival was reported to be 61% in patients taking aspirin versus 26.3% in patients not taking aspirin [118], and finally, the 3-year 
survival of US veterans with head and neck cancer was 79% in those taking aspirin, compared with only 56% of those not taking aspirin [92].
Using a different approach, a group in Liverpool used data for over 44,000 patients with colon cancer to derive a predictive equation which 
relates a number of factors present at diagnosis to survival [45]. Entering the details for a non-diabetic man aged 70 with colon cancer into 
the predictive formula, the inclusion of aspirin taking increases the estimate of survival by about 5 years, and for a woman, about 4 years.
Finally, as a test of the hypothesis posed in this report, we compared the association of aspirin and cancer mortality in the 15 less common 
cancers with cancer mortality in colon cancer. In this comparison, we use colon cancer mortality as the ‘gold estimate’ of the effect of aspirin 
on the grounds that the effect of aspirin has been more thoroughly investigated in colon cancer, than in any other cancer; colon cancer is 
the only cancer for which the UK National Institute for Clinical Excellence has given a limited recommendation for aspirin, [120] and the U.S. 
Preventive Services Task Force and other professional bodies give guidance for the use of aspirin in colon cancer [121].
This comparison shows:
   Colon Cancer mortality:
 24 studies give a pooled HR: 0.72 (95% CI: 0.63, 0.82),
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   Cancer mortality in less common cancers
 18 studies give a pooled HR: 0.79 (95% CI: 0.70, 0.88),
    Significant publication bias z = −2.8110, p = 0.0049.
Bleeding
A search for evidence on bleeding, and fatal bleeding attributable to aspirin was made, and this included writing to the corresponding author 
on all the 118 papers included in the three searches. Many of the studies however had been based on recorded data, with no direct contact 
with the patients involved, and authors of such reports had little or no knowledge about bleeding in the patients they described.
Many of the authors reported the expected excess in GI bleeding in the patients on aspirin. However, only a very few reported fatal bleeds. 
In one study, 3% of the patients taking aspirin and 3.2% of those not taking aspirin had had a fatal bleed [40]. Tsoi et al [49], who studied a 
cohort of over 18,000 patients with colon cancer reported that deaths of aspirin users who developed GI bleeding were 0.40%, compared 
with 0.36% of the patients not taking aspirin. A study of patients with liver cancer treated by transarterial chemoembolisation reported that 
six patients in the aspirin group and seven patients in the non-aspirin group died because of upper GI bleeding [93]. One paper makes men-
tion of the reduction in bleeding in patients who took a PPI along with the aspirin (OR: 0.85; 0.80, 0.91) [49]. All the references to bleeds 
relate to GI bleeds and no author made mention of cerebral bleeding.
Discussion
This report provides both confirmatory and new evidence on the benefit of aspirin in reducing mortality in patients being treated for cancer. 
Replication is an important procedure in science and the present study confirms the findings of our first report with 50 studies [7], and our 
second report with 29 studies [20]. The present study is a further replicate with 39 new observational studies.
The meta-analyses we now present are all based on pooling of the data provided by 118 observational studies comprising about a quarter 
of a million patients with cancer who were recorded as taking aspirin. This reveals that aspirin taking is associated with a reduction of cancer 
deaths of about one fifth in a range of 18 cancers (HR: 0.79 (0.73, 0.84) in 70 observational studies and OR: 0.67 (0.45, 1.00) in 11 studies 
(Table 2 and Supplementary Files 4 and 5). The effect of aspirin on all-cause mortality is closely similar (HR: 0.80 (0.74, 0.86) in 56 observa-
tional studies and OR: 0.57 (0.36, 0.89) in 7 studies). A reasonable interpretation of these results is – that at any time after a diagnosis of a 
wide range of different cancers, about 20% more of the patients who take aspirin are likely to be alive, compared with patients not taking 
aspirin.
The evidence of publication bias throughout this work is a most important issue. Bias due to the selective publication of positive findings for 
aspirin was expected, and for some of the pooled results the magnitude of this bias is greater than could be reasonably expected in chance 
grounds alone (Supplementary File 6). While conclusions drawn from these 118 papers have, therefore, to be cautious, the evidence is 
strengthened by the absence of significant bias at p < 0.05 for the data for colon cancer. It is also encouraging that the trim and fill analysis 
on the less common cancers maintained the beneficial TE for both cancer specific mortality and all-cause mortality.
Bleeding
A bleed, either GI or intra-cerebral, is a crisis for a patient, but the seriousness of a bleed attributable to aspirin should be evaluated against 
the likely benefits attributable to its use and furthermore the severity of the additional bleeds attributable to aspirin should be considered 
and not just their frequency [122, 123]. In relation to the treatment of cancer, our examination of the 118 reports gives a considerable degree 
of reassurance on aspirin, and particularly on the most serious bleeds. It is of relevance that most of the patients appear to have been taking 
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Low-dose aspirin is however associated with additional GI bleeds in between 0.8 and 5.0 patients per 1,000 person years aged 50–84 years 
in the general population [124]. This represents an increase above spontaneous GI bleeding of between about 50% [125] and 90% [121]. It 
is important to note that these increases imply that only one in every two or every three bleeds that occur in patients taking low-dose aspirin 
is likely to be truly attributable to the aspirin, the other bleeds being spontaneous and nothing to do with aspirin.
The most serious bleeds are those that lead to death and our concern on this led us, early in our investigations of aspirin and cancer, to 
conduct a careful evaluation of fatal bleeding [126] A meta-analysis based on 11 randomised trials showed that the additional bleeds attrib-
utable to aspirin are less serious than spontaneous bleeds and are seldom, if ever fatal (relative risk of death: 0.45; (0.25, 0.80), and the risk 
of a fatal bleed in the totality of subjects randomised to aspirin, relative to subjects randomised to placebo was RR: 0.77 (0.41, 1.42). As we 
reported in our overview [126], others have reported similar findings of a reduction in the proportion of fatal bleeds in patients taking aspirin 
[9, 127–130].
Findings on bleeding in the recent ASPREE trial of prophylactic aspirin are of interest as more than 19,000 subjects with a median age of 74 
years were followed for 5 years. Eighty-nine subjects randomised to aspirin, or 1.9 in every 1,000 experienced a bleed each year, compared 
with 48 bleeds, or just over 1.1 per thousand per year in those not taking aspirin. Granted this was not a trial of aspirin treatment, but it is of 
relevance to the safety of the drug that only two fatal bleeds occurred, and neither was in a subject taking aspirin [131].
The most serious side effect of aspirin, intra-cerebral bleeding, is fortunately rare [132], and no author in our literature review mentioned 
cerebral bleeding within the patients they followed. The risk associated with aspirin is estimated to be around 1.39 (95% CI: 1.08, 1.78) [125] 
equivalent to one or two additional haemorrhagic strokes per year in every 10,000 subjects [133].
Hypertension is the major factor in haemorrhagic stroke and in one major overview of randomised trials there was a doubling of cerebral 
haemorrhages for a rise of 20 mmHg in blood pressure (RR: 2.18; 95% CI: 1.65, 2.87) [127]. The relevance of hypertension was further high-
lighted in a trial of aspirin based on 20,000 patients with hypertensive disease, all of whom were adequately treated with anti-hypertensive 
drugs. There were no additional cerebral bleeds attributable to aspirin: the same number of patients on aspirin experienced cerebral bleeds 
(19 patients) as those on placebo (20 patients) [133].
Strengths and limitations of this study
In addition to the risks of publication bias as detailed above, a most important limitation is that almost all the evidence we present are from 
observational studies. A number of randomised trials of therapeutic aspirin are in progress but these focus entirely on either one, or a few 
of the common cancers: colon [12–15], breast [12, 14] and prostate [12, 15]. Our concern, however, is for all cancers and not one or a few 
cancers, and as others have pointed out many of the actions of aspirin on cancer development, growth and metastatic spread, appear likely 
to be relevant to a wide range of cancers [6–19].
It is important to note that amongst the uncertainties in these observational studies, two uncertainties appear to stand out in their prob-
able relevance to every observational study, and to the possible size of their effects. These are: first: uncertainties about the classification 
of patients with regard to continuous aspirin taking, and uncertainties about the non-taking of aspirin by the ‘controls’, and secondly, co-
morbidity in the patients taking aspirin.
Few authors give reassurance about continued aspirin taking during follow-up, and no authors comment on the possibility of ‘contamination’ 
of control subjects starting to take ‘over the counter’ aspirin during the follow-up. An additional column in Supplementary File 3 lists quota-
tions from the papers reviewed and these show that most authors assumed that if there is evidence of aspirin taking at the time of diagnosis, 
it can reasonably be assumed that aspirin taking was continuous during follow-up. Thus, ‘Low-dose aspirin use was defined as a minimum 
of one filled prescription after cancer diagnosis’ [89] and another: ‘the patients were receiving aspirin from diagnosis to at least 1 year after 
treatment initiation’ [90]. One author pointed out however that ‘the inverse association with aspirin appeared to be only among men who 
reported using aspirin regularly’, [76] and another noted that a reduction in mortality was ‘notably among patients filling prescriptions for 
a large quantity of low dose aspirin tablets during the (follow-up) period [77]. Another author found that prescribed aspirin alone was not 
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A recent study by a group in Dublin examined the influence of approaching death on end-of-life aspirin use in patients with breast or colorec-
tal cancer. They found that the use of aspirin declined ‘considerably’ during the 2 years before death, and at the time of death rates of aspirin 
use had dropped from around 60% to around 20% for colorectal cancer and from around 80% to around 45% for breast cancer [134].
The only comment about aspirin taking by control subjects comes from an overview of 12 studies in which the authors state that the pooled 
survival in patients on aspirin was only HR: 0.96 (0.88, 1.04) but if non-aspirin taking was more tightly defined as less than once per week, 
the HR was 0.89 (0.82, 0.98) [135].
The other important limitation is confounding by co-morbidity. Many authors mention that the aspirin takers in their study were older than 
the control patients not on aspirin. While this can be adjusted for statistically, the fact that a number of studies state that most of the patients 
who were taking aspirin were doing so because of a prior vascular event or prevalent vascular disease. Clearly, the morbidity that had led 
some of the patients to take aspirin can have eroded any benefit achievable by aspirin and while many of the papers mention this, few give 
details.
Yet a further limitation arises from possible miscoding of the causes of death in these studies. In the SEER programme on mortality in patients 
with cancer in the USA, it was found that 11% of cancer deaths had been attributed to vascular disease [136]. Any such miscoding will lead 
to an underestimate of the reduction in cancer deaths associated with aspirin.
The very broad range in the estimates of effect of aspirin leading to high heterogeneity estimates in our meta-analyses is worrying, and some 
of the differences between studies seem to defy any reasonable explanation. And yet, this was predicted from the beginning of the work on 
aspirin treatment [7]. There are many biases and sources of possible differences between the series of patients in the various studies, includ-
ing differences in age and social factors, differences in other treatments and in general clinical management [41, 48]. Then there are possible 
differences in consistency of aspirin taking and the differences in co-morbidity already mentioned. Both poor aspirin taking and co-morbidity 
in patients taking aspirin will increase heterogeneity, and are probably inevitable in a series of studies such as we present. On the other hand, 
it seems unlikely that such differences could account for the overall benefits we find to be associated with aspirin taking.
Conclusions
We judge that the body of evidence now available on the efficacy and the safety of aspirin justifies its use as an adjunct treatment in a wide 
range of cancers. Clinical care includes an ethical imperative for shared decision making [137] and we, therefore, believe that doctors should 
present, and patients with cancer should be encouraged to raise the topic of aspirin taking with their doctors. At the same time, we stress 
that aspirin is not a possible alternative to any other treatment, although in poorer countries aspirin could be one of very few, or perhaps the 
only acceptable treatment on the grounds of cost and availability [138].
Further research into aspirin and cancer would clearly be of great value, and studies including observational and randomised trial should be 
encouraged, especially if focused upon one of the less common cancers.
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Supplementary materials
Supplementary File 1. Search strategy.
SUPPLEMENTARY FILE 1
ASPIRIN AND CANCER SURVIVAL IA systematic review and meta-analyses  
of 118 observational studies of aspirin and 18 cancers
Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante,  
Janet Pickering, John Watkins, Alison Weightman, Delyth Morris
Search strategy
Search strategy developed using the following search filters for study design.
• Observational studies: SIGN filter (http://www.sign.ac.uk/methodology/filters.html#obs)
• Randomised controlled trials: Cochrane highly sensitive search filter (http://handbook.cochrane.org/chapter_6/box_6_4_c_cochrane_
hsss_2008_sensmax_ovid.htm)
MEDLINE and Medline in Process (searched 11 March 2020)
1. randomized controlled trial.pt.









11. exp case control studies/
12. exp cohort studies/
13. Case control.tw.
14. (cohort adj (study or studies)).tw.
15. Cohort analy*.tw.
16. (Follow up adj (study or studies)).tw.






23. 9 or 22
24. exp animals/ not humans.sh.
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27. (cancer* or malign* or tumour* or tumor*).tw
28. 26 or 27
29. Aspirin/
30. (aspirin* or “acetylsalicylic acid”).tw
31. 29 or 30
32. 25 and 28 and 31
33. Limit 32 to ed”20180529-20200311”
EMBASE (searched 11 March 2020)
1. Random*.tw
2. Clinical trial*.mp










13. (Cohort adj (study or studies)).mp.
14. (Case control adj (study or studies)).tw.
15. (follow up adj (study or studies)).tw.
16. (observational adj (study or studies)).tw.
17. (epidemiologic* adj (study or studies)).tw.
18. (cross sectional adj (study or studies)).tw.
19. or/6-18
20. 5 or 19
21. exp animal/ not human.sh.
22. 20 not 21
23. Exp neoplasms/
24. (cancer* or malign* or tumour* or tumor*).tw
25. 23 or 24
26. Aspirin/
27. (aspirin* or “acetylsalicylic acid”).tw
28. 26 or 27
29. 22 and 25 and 28
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Supplementary File 2. Details of the new studies included in the review.
A systematic review and meta-analyses  
of 118 observational studies of aspirin and 18 cancers
Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante, 
Janet Pickering, John Watkins, Alison Weightman, Delyth Morris
SUPPLEMENTARY FILE 2
Description of papers identified in the 2021 literature search.
Those which reported Hazard Ratios (HRs) are shown first, 
followed by those which reported RRs, OR, etc. 
Details of papers identified in the literature searches in 2016 are given in Elwood et al [7] 
and those identified in the 2018 search are given in Elwood et al [20].
1. Studies in which results are reported as hazard ratios
Source Organ Type of study and No.
Number in the cohort
Length of follow-up








212 deaths Data on aspirin and PIK3CA status 
concludes that restriction of aspirin to 
patients with the mutation should be 
unreasonable
8






Above paper on patients in N.I., this one 
closely similar with a cohort of patients 
in Scotland
8






Data given on PIK3CA 4




9,026 deaths Marginal increase in fatal bleeding in 
aspirin users
8




241/834 Aspirin associated with a reduction in 
deaths in patients with stage I cancer
8











Breast Prospective cohort 







Complex design of study.  Random 
allocation of two drugs and after 4 
years one of these stopped
4




n.a. Effect of aspirin greater when pattern 
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Source Organ Type of study and No.
Number in the cohort
Length of follow-up








n.a. Exclusion of women with negative 
hormone receptor  
Relates tumour PIK3CA interaction to 
clinical outcomes only 70% on aspirin
6




7,633 deaths Reduction associated with aspirin was 
notably among patients filling scripts for 
a large quantity of aspirin tablets 
8
Hurwitz et al [76] Prostate Prospective cohort 97 men
FU up to 25 years
97 cancer 
deaths
Association of deaths with aspirin…’ 
appeared only to be among men who 
reported using aspirin regularly
8
Prause et al [78] Prostate Prospective 
cohort
789/3,525
FU 9.6 years 
Only 3 deaths 
from prostate 
cancer







13,715 5,138 Data given for oesophagus, stomach, 
pancreas, 
liver, colon and rectum deaths
8













Separate patients with oesophageal 
cancer and other with gastric cancer, 
within the same cohort
Some uncertainty about aspirin taking 
long term
7




53,344 and 6,986 on 
aspirin
n.a. Reported as median survivals. In 
response to an email a hazard ratio was 
supplied by the author
5











3,635 patients n.a. Associations were comparable by 








Non-aspirin NSAIDs had a similar 
reduction to that of aspirin
7
Merritt et al [85] ovary Prospective US 
Nurses Hlth 1 
and 2
964 512 cancer 
deaths
Pts who became recent users of ASA 
(HR 0.44 (0.26, 0.74))
8




242/1,661 Danish population wide study 8






Aspirin users more likely to have early 
stage disease
Aspirin takers followed up for one year 










Study limited to PIK3CA positive 
patients
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Source Organ Type of study and No.
Number in the cohort
Length of follow-up










18 months extra survival on ASA
Six fatal bleeds on aspirin, 7 in non 
aspirin
8






All pts had had Hepatitis 5-15 years 
previously










on ASA 64 
not
Additional survival judged to be due 
to prolonged metastasis-free interval 
associated with aspirin taking
8






No evidence of effect on distant 
metastases
8
Sperling et al [89] Endometr. Prospective cohort 6,694
FU 4.5 years
n.a. A nationwide study 7




2,415 deaths Higher comorbidity in aspirin users 7






Propensity score matched control 
patients
8




n.a. Data on aspirin dose and duration 
mostly lacking
7




n.a. Inverse association between aspirin use 
and mortality in stage II and III, but not 
in stage I
8




79/201 ASA plus statin – implies high co-
morbidity?
Compliance with ASA taking 81% ASA’
6
Reports on ‘other’ cancers, described in our report published in 2016 (Elwood et al [7]): 
 [83] Nagle et al (2015)  Ovarian cancer
 [108]  Fontaine et al (2010) Lung cancer  
 [112] Pastore et al (2015) Bladder cancer
 [80] Chae et al (2013)  Mix of female cancers
 [79] Chae et al (2014)  Lymphocytic cancer
 [88] McFarlaine et al (2015)   Head and neck
Reports on ‘other’ cancers, described in our report published in 2018 (Elwood et al [20]): 
 [84] Bar et al (2016)  Ovarian cancer
 [87] Matuso et al (2016) Endometrium
 [93] Li et al (2016)  Liver cancer
 [39] Veitonmaki et al (2016) Lung
 [94] Maddison et al (2017 Lung
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2. Studies in which results are reported as RRs, ORs, etc.
Source Organ Type of study and No.
Number in the cohort
Length of follow-up




Din et al 
[109]
Colon Case/control drawn 
from a trial cohort
234/526
FU n.a.
125/761 NSAIDs but data for aspirin given
Reimers et al 
[105]
colorectal Cohort study 178/784 69 deaths in 
users 380 in non-
users
HLA Class 1 antigen amalgamated 8
Holmes et al 
[115]
Breast Prospective study 27,426
FU 2.5 years
565/173 Daily aspirin associated with a reduction 
in deaths (HR 0.69)
Less than daily associated with excess 
deaths (HR 1.43)
8
Bowers et al 
[110]






NSAIDS. 81% of patients took aspirin 7
Kwan et al 
[116]
Breast Cohort of 2,292 
women
FU 2.5 years 41/209 recurrent 
cancers
NSAIDs study. only 18 patients(7%) took 
aspirin post diagnosis
8

































n.a. A PhD thesis based on nationwide data 6








n.a. Pts who filled more than one prescription, 
excluding refills, after diagnosis of HNC 
were considered ASA users
7
Gupta et al 
[114]
bladder Prospective study 15/88
FU 18 months
recurrence Very small numbers. High incidence (75%) 
of vascular disease. Also treated with BCG 
therapy
4








n.a. Metastases free in 88% of ASA patients; 
77% not on ASA
3






17/184 Data on cancer mortality stated as an 
HRData on all-cause death used for an 
OR
8
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Supplementary File 3. Results: estimates of association: aspirin and mortality.
A systematic review and meta-analyses  
of 118 observational studies of aspirin and 18 cancers
Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante, 
Janet Pickering, John Watkins, Alison Weightman, Delyth Morris
SUPPLEMENTARY FILE 3
Results of studies identified in the 2021 literature search.
Those which reported Hazard Ratios (HRs) are shown first, 
followed by those which reported RRs , OR, etc. 
Results of studies identified in the literature searches in 2016 are given in Elwood et al [7] 
and those identified in the 2018 search are given in Elwood et al [20]
1. Studies in which results are reported as hazard ratios
Source Organ ASA/noneF-U
Evidence for  
continued
aspirin taking
































 pts on ASA 
HR 1.63
8





‘75mg aspirin at 
diagnosis






Data given on  
PIK3CA
4








Data on GI 
bleeding 
RR 1.09 on 
aspirin
8









In Stage 1 
8
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Source Organ ASA/noneF-U
Evidence for  
continued
aspirin taking
































































2 or more scripts














Hurwitz et al 
[76]








 at diagnosis 
selected
5
















1008/13,715 Prescription records 1008/8278 362/4776 HR 0.52
0.44, 0.63
8
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Source Organ ASA/noneF-U
Evidence for  
continued
aspirin taking









































Verdoot et al 
[86]
















































































Lyon et al [98] bladder 461/600
4.2 years
‘aspirin users 















‘a minimum of one 
filled
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Source Organ ASA/noneF-U
Evidence for  
continued
aspirin taking











Jackson et al 
[101]
Gallbladder 605/2,934 ‘aspirin was defined 
as 





















Luo et al [102] Nasopharynx 113/452
FU 10 years
Defined as 



















































 aspirin plus 
statins
6
Papers on ‘other’ cancers, described in our report published in 2016 (Elwood et al [7]): 
 Nagel et al [83] (2015)
 Fontaine et al [108] (2010)
 Pastore et al [112] (2015)
 Chae et al [80] (2013)
 Chae et al [79] (2014)MacFarlane et al [88] (2015)
Papers on ‘other’ cancers, described in our report published in 2018 (Elwood et al [20]): 
 Bar et al [84] (2016)
 Matuso et al [87] (2016)
 Li et al [93] (2016)
 Veitonmaki et al [39] (2015)
 Maddison et al [94] (2017)
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2. Studies in which results are reported as RRs, ORs, etc.
Source Organ ASA/noneF-U













Din et al 
[109]
Colorectal 354/526 ‘We did not have info 
on 
aspirin after cases were
 diagnosed’
125, 761 OR 0.78  
(0.65, 0.92)





Colon 107,429 Users had at least on 
script
For aspirin for 14 days







No assessment of 
aspirin
 taking in 33%t

















Use of aspirin or 
NSAID
‘at least 3 days/week’









































Aspirin taking pre-op .









‘at least one script for 



















‘number, date and dose 

















1.5 to 6 years
‘particular attention to




Gupta et al 
[114]
Bladder 15/88FU 11 
months
ASA taken for 
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Source Organ ASA/noneF-U













































ecancer 2021, 15:1258; www.ecancer.org; DOI: https://doi.org/10.3332/ecancer.2021.1258 31
Supplementary File 4. Forest plots for estimates of aspirin and mortality as HRs.
Supplementary file 4
ASPIRIN AND CANCER SURVIVAL I.
A systematic review and meta-analyses 
of 117 observational studies of aspirin and 18 cancers
Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante, 
Janet Pickering, John Watkins, Alison Weightman, Delyth Morris
Five forest plots of aspirin and deaths from cancer: 
Colon, breast, prostate, other cancers, all cancers
Five forest plots of aspirin and deaths from all-causes: 
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Supplementary File 5. Forest plots for aspirin and mortality as ratios other than HR.
ASPIRIN AND CANCER SURVIVAL I.
A systematic review and meta-analyses 
of 114 observational studies of aspirin and 18 cancers
Peter C Elwood, Gareth Morgan, Christine Delon, Majd Protty, Julieta Galante, 
Janet Pickering, John Watkins, Alison Weightman, Delyth Morris
Supplementary file 5
Associations reported a ORs RRs and percentage survival 
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Supplementary File 6. Estimates of publication bias.
Publication Bias, Funnel plots
All cancers combined
All cancers combined mortality
13 cases added with Trim and fill
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = −3.3121, p = 0.0009
Bias
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = −3.8370, df = 68, p = 0.0003
Bias
            Intercept ConfidenceInterval      t       p
Egger’s test    -0.413       -1.393-0.567 -0.797 0.42811
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All Cancers Combined Cancer mortality:
Trim and Fill and Cumulative forest plot ranked by SE with trim and fill.
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Cumulative forest plot ranked by SE with Trim and fill at end.
Published value 0.79 (0.73, 0.84)
Results with trim and fill 0.85 (0.79, 0.91)
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All Cancers Combined All-Cause Mortality
19 cases added with Trim and fill
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = −4.0797, p < 0.0001 
Bias
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = −4.5330, df = 54, p < 0.0001 
Bias
            Intercept ConfidenceInterval      t       p
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All Cancers Cancer All-Cause mortality:
Trim and Fill and Cumulative forest plot ranked by SE with trim fill
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Cumulative forest plot ranked by SE with Trim and fill at end. 
Published value 0.80 (0.74, 0.86)
Results with trim and fill 0.94 (0.87, 1.02)
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Breast Cancer
Breast Cancer Mortality
Six cases added with Trim and fill
regtest(BreastResultREML, model = «rma», predictor = «sei»)
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = -1.6897, p = 0.0911
Some Bias 
at p=0.1 level
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = -2.1738, df = 11, p = 0.0524
Some Bias 
at p=0.1 level
             Intercept        ConfidenceInterval      t       p
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Breast Cancer Mortality:
Trim and Fill and  Cumulative forest plot ranked by SE with trim fill
Forest plot ranked by SE with trim and fill mirrored studies added below. 
Cumulative forest plot ranked by SE with Trim and fill at end.
Published value 0.84 (0.72, 0.98)
Results with trim and fill 1.00 (0.85, 1.19)
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Breast Cancer All-Cause Mortality
Zero cases added with Trim and Fill
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = −0.2868, p = 0.7743
No
Bias seen 
But n too low
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = −0.2147, df = 7, p = 0.8361
No
Bias seen  
But n too low
             Intercept ConfidenceInterval      t       p
Egger’s test    -0.088       -5.772-5.596 -0.031 0.97639
Warning: The meta-analysis contains k = 9 studies. Egger’s test may lack the statistical power to detect bias 
when the number of studies is small (i.e., k < 10).
No Bias seen  
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Breast Cancer All-Cause mortality:
Trim and Fill and Cumulative forest plot ranked by SE with trim fill
Forest plot ranked by SE. 
No Trim and fill as no cases added.
Cumulative forest plot ranked by SE. No Trim and fill.
Published value 0.94 (0.70, 1.25)A
The same
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Colon Cancer
Colon Cancer Mortality, 
No cases added with Trim and fill
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = −0.7276, p = 0.4668
No Bias
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = −0.7568, df = 22, p = 0.4572
No Bias
             Intercept ConfidenceInterval     t       p
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Colon Cancer mortality: Cumulative forest plot ranked by SE.
Published value 0.72 (0.63, 0.82)
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Colon Cancer All-Cause Mortality
Eight cases added with Trim and fill
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = −2.7423, p = 0.0061
Bias
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = −3.8054, df = 18, p = 0.0013
Bias
             Intercept ConfidenceInterval      t       p
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Colon Cancer All-Cause mortality:
Trim and Fill and Cumulative forest plot ranked by SE with trim fill
Forest plot ranked by SE with trim and fill mirrored studies added below. 
Cumulative forest plot ranked by SE with Trim and fill at end. 
Published value 0.83 (0.75, 0.92)
Results with trim and fill 0.97 (0.87, 1.07)
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Other Cancers
Other Cancers Mortality
Five cases added with Trim and fill
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = −2.8110, p = 0.0049
Bias
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = −3.4563, df = 16, p = 0.0033
Bias
             Intercept ConfidenceInterval      t       p
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Other Cancers Cancer mortality: 
Trim and Fill and Cumulative forest plot ranked by SE with trim fill
Forest plot ranked by SE with trim and fill mirrored studies added below. 
Cumulative forest plot ranked by SE with Trim and fill at end. 
Published value 0.79 (0.70, 0.88)
Results with trim and fill 0.86 (0.77, 0.98)
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Other Cancers All-Cause Mortality
Seven cases added with Trim and fill.
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = −1.9277, p = 0.0539
Bias 
at cutoff p < 0.1
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = −2.6072, df = 19, p = 0.0173
Bias
             Intercept ConfidenceInterval      t       p
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Other Cancers All-Cause Mortality
Trim and Fill and Cumulative forest plot ranked by SE with trim fill
Forest plot ranked by SE with trim and fill mirrored studies added below. 
Cumulative forest plot ranked by SE with Trim and fill at end.
Published value 0.67 (0.60, 0.75)
Results with trim and fill 0.74 (0.66, 0.83)
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Prostate Cancer
Prostate Cancer Mortality
Six cases added with Trim and fill.
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = −2.0812, p = 0.0374
Bias
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = −3.1051, df = 13, p = 0.0084
Bias
             Intercept ConfidenceInterval      t       p
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Prostate Cancer mortality
Trim and Fill and Cumulative forest plot ranked by SE with trim fill
Forest plot ranked by SE with trim and fill mirrored studies added below. 
Cumulative forest plot ranked by SE with Trim and fill at end. 
Published value 0.89 (0.78, 1.02) 
Results with trim and fill 1.00 (0.87, 1.14)A
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Prostate Cancer All-Cause Mortality
Two cases added with Trim and Fill
Regression Test for Funnel Plot Asymmetry
model:     mixed-effects meta-regression model
predictor: standard error
test for funnel plot asymmetry: z = −1.1081, p = 0.2678
No evidence of 
Bias but too few 
studies
Regression Test for Funnel Plot Asymmetry
model:     weighted regression with multiplicative dispersion
predictor: standard error
test for funnel plot asymmetry: t = −1.0350, df = 4, p = 0.3591
No evidence of 
Bias but too few 
studies
             Intercept ConfidenceInterval      t       p
Egger’s test    -2.697       -9.361-3.967 -0.798 0.46976
Warning: The meta-analysis contains k = 9 studies. Egger’s test may lack the statistical power to detect bias 
when the number of studies is small (i.e., k < 10).
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Prostate Cancer All-Cause mortality:
Trim and Fill and Cumulative forest plot ranked by SE with trim fill
Forest plot ranked by SE with trim and fill mirrored studies added below. 
Cumulative forest plot ranked by SE with Trim and fill at end. 
Published value 1.00 (0.78, 1.27)A
Results with trim and fill 1.13 (0.88, 1.43)A
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Egger’s test
On ORs for 10+ studies of cancer-specific mortality meta-analysis for all cancers
Regression-based Egger test for small-study effects
Random-effects model
Method: REML




     Prob > |z| =    0.5011 (this is the p value)
 
No evidence of publication bias.
